Get yours at the Merch Shop!
Timothy Leary on LSD…
Tag: psychedelics
Psychedelic use linked to reduced distress, increased social engagement in autistic adults
A recent study has found that some autistic adults report lasting improvements in their mental health and social lives after using psychedelic drugs. The research, published in the journal Psychopharmacology, revealed that a significant number of autistic individuals attributed reductions in distress and social anxiety, along with increased social engagement, to a single, impactful psychedelic experience. However, the study also highlighted that a minority of participants experienced negative effects, emphasizing the need for caution and further research in this area.
There is a growing interest in the potential of psychedelic drugs to treat various mental health conditions, such as depression and post-traumatic stress disorder, in the general population. Autism spectrum disorder, a developmental condition characterized by challenges in social interaction and communication, as well as repetitive behaviors, often co-occurs with mental health difficulties. Autistic individuals are known to experience higher rates of anxiety, depression, and loneliness, and often report a lower quality of life compared to non-autistic people.
While psychedelics are being explored as therapies for mental health in broader populations, there is very little scientific understanding of how these substances affect autistic individuals specifically. Some anecdotal accounts suggested that psychedelics might be helpful for autistic people, potentially by improving their understanding of themselves and their emotions, but rigorous research was lacking. The new study aimed to investigate the experiences of autistic adults who have used psychedelics and to understand if they perceived any changes in their mental health and social abilities as a result.
To conduct their investigation, the researchers used an online survey to gather information from adults who identified as autistic. Participants were recruited through advertisements on social media platforms, online forums related to psychedelics and autism, and by collaborating with an organization called the Autistic Psychedelic Community. The advertisements were carefully worded to encourage participation from individuals with both positive and negative psychedelic experiences. To be included in the study, participants had to be at least 18 years old, fluent in English, and either have a formal diagnosis of autism from a healthcare professional or self-identify as autistic. They also needed to have used a psychedelic substance at least once in their lives.
A total of 284 people completed the survey. For their analysis, the researchers focused on 233 participants who reported that their most ‘impactful’ psychedelic experience involved a classic psychedelic drug, such as lysergic acid diethylamide (LSD) or psilocybin (the active compound in magic mushrooms). The other participants who were excluded from the main analysis had reported that their most impactful experience was with substances like MDMA, cannabis, or ketamine.
Federal Court Rejects Washington Doctor’s Effort To Legally Access Psilocybin For End-Of-Life Patient Care
A federal appellate court has rejected the latest effort by a Washington State doctor who is seeking to legally use psilocybin to treat cancer patients in end-of-life care, ruling that the Drug Enforcement Administration (DEA) provided a reasonable explanation in denying the doctor’s request.
In an opinion filed on Thursday, a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit rejected arguments from lawyers for Dr. Sunil Aggarwal and his clinic, the Advanced Integrated Medical Science (AIMS) Institute that DEA’s denial of Aggarwal’s efforts was arbitrary and capricious
“DEA’s decision to deny AIMS’s request was neither arbitrary nor capricious,” the court concluded. “We therefore deny AIMS’s petition for review of the DEA’s decision.”
Aggarwal and AIMS have been working since at least 2020 to find a way to legally obtain psilocybin for patients in palliative care, initially seeking to win permission from regulators under state and federal right-to-try laws.
When DEA rebuffed that request, Aggarwal sued. In early 2022, a federal appellate panel dismissed the lawsuit, opining that the court lacked jurisdiction because DEA’s rejection of Aggarwal’s administrative request didn’t constitute a reviewable agency action.
The latest Ninth Circuit ruling results from Aggarwal’s responses to that ruling. In February 2022, the doctor filed a formal petition with DEA to reschedule psilocybin from Schedule I to Schedule II under the federal Controlled Substances Act (CSA)—the denial of which is a reviewable action. He also applied for a regulatory waiver to obtain psilocybin.
DEA denied Aggarwal’s petition in September 2022 and rejected the waiver request the next month. The doctor’s Ninth Circuit case challenged both decisions.
“Following the dismissal of its earlier petition, AIMS returned to DEA with a concrete request. AIMS asked EA to exempt Dr. Aggarwal from registration under the CSA, either by finding that Dr. Aggarwal’s proposed use of psilocybin was not covered by the CSA’s registration requirement or by waiving the registration requirement,” Judge Marsha Berzon, a Clinton appointee, wrote for the court in Thursday’s opinion. “DEA declined to take action, and AIMS again petitioned for review. Because DEA’s response was neither arbitrary nor capricious, we deny AIMS’s petition for review.”
New York Bill Would Legalize Psychedelics Like Psilocybin, Mescaline And Ibogaine
Another psychedelics bill has been prefiled in New York for the 2025 session—this one calling for the legalization of certain entheogenic substances such as psilocybin and ibogaine for adults 21 and older.
Sponsored by Assemblymember Linda Rosenthal (D), along with eight cosponsors, the legislation would amend state statute to make legal the “possession, use, cultivation, production, creation, analysis, gifting, exchange, or sharing by or between natural persons of twenty-one years of age or older of a natural plant or fungus-based hallucinogen.”
DMT, ibogaine, mescaline, psilocybin and psilocyn would fall under the definition of “natural plant or fungus-based hallucinogens” that would be legalized by the bill.
Further, the legislation would authorize people to engage in psychedelic services “with or without remuneration,” as well as use the entheogens in religious ceremonies.
State and local law enforcement would be prohibited from cooperating or providing assistance to the federal government for the purpose of enforcing controlled substances laws against activities made legal under the state law.
The measure goes on to outline a series of protections: People couldn’t lose professional licenses, public assistance or be denied mental health or behavioral health services simply for using psychedelics. And their lawful use also couldn’t be the sole basis for a child welfare investigation.
New York localities wouldn’t be allowed to enact laws criminalizing psychedelics, but they could “adopt and implement legislation and policies which bear directly on or are related to natural plant or fungus-based hallucinogens in furtherance” of the bill.
Finally, the proposal would remove psilocybin, psilocyn, DMT, mescaline and ibogaine from the state’s banned substances list.
The Day the Pope Met a Psychedelic Evangelist
The pope met an emissary from the psychedelic world at a “holy meeting” at the Vatican, where a Jesuit lawyer named Brian Muraresku presented Pope Francis with a manifesto for a psychedelic “New Reformation.”
Popes and reformations do not historically get along, but Francis accepted a copy of Muraresku’s 2020 book The Immortality Key at the meeting, which took place in late 2021 or early 2022. The book argues that psychedelics might rescue a “dying faith” and save Western civilization.
Though the science journalist Michael Pollan has called it “groundbreaking,” The Immortality Key is largely a rehash of others’ work shaped into a dubious Da Vinci Code–style thriller. Trade publishers would otherwise have little interest in a 400-page goose chase for what intoxicants the oracles and prophets might have been smoking or sipping, and so the book begins with a message for today. Western civilization, Muraresku argues, is in the grip of a cataclysmic “spiritual crisis” that can be remedied only through a “popular outbreak of mysticism,” the result of retrieving what he says are the Eucharist’s ancient, and until now secret, pharmacological roots.
And what are those roots? Muraresku is convinced that Christianity evolved from pagan mystery cults whose most sacred ritual involved the ingestion of a psychedelic fungus—and that this sacrament, the kykeon, eventually became the Holy Eucharist.
A protégé of Graham Hancock (an Economist reporter turned conspiracy theorist who has made a fortune writing speculative bestsellers about purported lost civilizations), Muraresku has written that “about seventy-five percent would leave the FDA-approved house church permanently transformed. And ready to begin a lifelong spiritual journey that could, once again, make life livable on this planet. This should begin happening by 2030, if not sooner.”
First Patient Dosed In Historic Study On Whether LSD Effectively Treats Anxiety
For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized anxiety disorder (GAD).
Drugmaker MindMed says that the trial, dubbed Voyage, is eventually expected to enroll about 200 people in the U.S. and will compare the effects of its proprietary LSD product to a placebo. A second Phase 3 trial, called Panorama, will also be conducted in both the U.S. and Europe and is expected to kick off in the first half of next year.
“Today marks a pivotal moment in our journey towards advancing a novel treatment option for the 20 million people in the U.S. living with GAD,” MindMed’s chief medical officer, Daniel R. Karlin, said in a statement released on Monday. “Building on our scientifically rigorous Phase 2b study, which demonstrated efficacy that far exceeds today’s standard of care and a favorable tolerability profile, our Phase 3 studies are designed to adhere to the highest clinical and ethical standards and are in alignment with guidance from the U.S. Food and Drug Administration.”
In March of this year, the Food and Drug Administration (FDA) granted MindMed’s LSD product “breakthrough therapy” status as a treatment for GAD. That followed a Phase 2 trial showing that a single oral dose of LSD led to “clinically and statistically significant” reductions in anxiety scores 12 weeks after administration, with 65 percent of participants showing a clinical response and 48 percent in clinical remission following the treatment.
Breakthrough drug status is meant to recognize the therapeutic promise of an emerging substance or therapy as well as speed the research and development of treatments that fill an unmet need. MDMA and psilocybin have also previously been awarded the designation.
The new research will use dissolvable oral tablets of the drug, MM120 ODT, or lysergide D-tartrate, which MindMed describes as a “proprietary and pharmaceutically optimized form of LSD.”
The first Phase 3 study, Voyage, will last a year and consist of two parts: a 12-week randomized, double-blind, placebo-controlled study to see how LSD affects anxiety symptoms. That will be followed by a 40-week extension period, during which participants can access open-label treatment with the drug based on the severity of their anxiety symptoms.
LSD has a noticeable subjective effect on sensation and cognition, which means it’s likely participants will know whether they received the psychedelic or a non-psychoactive placebo.
DEA Calls For Increased DMT Production In 2025 To Support Development Of FDA-Approved Psychedelic Drug
The Drug Enforcement Administration (DEA) is increasing the 2025 quota for the legal production of DMT in the U.S., saying it agrees with requests for the adjustment to “support legitimate research and scientific efforts” to develop a Food and Drug Administration- (FDA) approved drug based on the psychedelic.
In a notice set to be published in the Federal Register on Tuesday, DEA cited “additional quota applications and comments from DEA-registered manufacturers,” justifying the increase for the psychedelic compound.
DEA released initial quotas for the production of Schedule I and Schedule II controlled substances for research purposes in September. At the time, it called for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA.
But following a public comment period, it raised the production goal for DMT from 11,000 grams to 20,000 grams.
It’s not clear how close researchers are to developing a DMT-based drug, but several companies have indicated their intent to bring the psychedelic to market, pending regulatory approval.
It’s all political theatre…
Get yours HERE!
A Psychedelic Ban Would Disrupt Important Research
You have probably never heard of 2,5-dimethoxy-4-iodoamphetamine (DOI), much less worried about its possible abuse. Yet the Drug Enforcement Administration (DEA) wants to ban this synthetic psychedelic, a promising research chemical used in more than 900 published studies, by placing it in Schedule I of the Controlled Substances Act. Students for Sensible Drug Policy (SSDP), which defeated a previous DEA attempt to ban DOI in 2022, is determined to stop the agency’s interference with science again.
A DEA administrative law judge has scheduled a 10-day hearing on the proposed ban, beginning on November 12. SSDP, which filed a prehearing statement on behalf of more than 20 scientists, argues that placing DOI in Schedule I would impose “onerous financial and bureaucratic obstacles on researchers.” SSDP also opposes the scheduling of another psychedelic, 2,5-dimethoxy-4-chloroamphetamine (DOC), under the same proposed rule, which the DEA published last December.
“DOI and DOC are important research chemicals with basically no evidence of abuse,” says SSDP alum and legal counsel Brett Phelps. Phelps is working with Denver attorney Robert Rush, who represents University of California, Berkeley, neuroscientist Raul Ramos.
“The DEA’s attempt to classify DOI, a compound of great significance to both psychedelic and fundamental serotonin research, as a Schedule I substance exemplifies an administrative agency overstepping its bounds,” Rush says. “The government admits DOI is not being diverted for use outside of scientific research yet insists on placing this substance in such a restricted class that it will disrupt virtually all current research.”
SSDP describes the two compounds as “essential research chemicals in pre-clinical psychiatry and neurobiology,” noting that their unscheduled status has made them accessible as tools for studying serotonin receptors. It says DOI, in particular, has been “a cornerstone in neuroscience research” due to its selectivity for the 5-HT2A serotonin receptor, crucial for understanding the therapeutic effects of psychedelics. Scientists have used DOI to “map the localization of an important serotonin receptor in the brain critical in learning, memory, and psychiatric disease,” SSDP notes, and DOI studies “have shown encouraging results in managing pain and reducing opioid cravings.”
The DEA argues that DOI and DOC “have a high potential for abuse.” While the two compounds “are available for purchase from legitimate chemical synthesis companies,” the DEA concedes, “there is no evidence of diversion from these companies.” But it notes that both drugs “have been encountered by law enforcement in the United States,” indicating their “availability for abuse.” Because “DOI and DOC are not found in FDA-approved drug products,” the DEA says, people who use them must be doing so “on their own initiative, rather than based on medical advice.”
JD Vance Asks Joe Rogan For Advice On Providing Psychedelics Access To Veterans After Being ‘Fascinated’ By Drug War History Lesson
Sen. JD Vance (R-OH), former President Donald Trump’s vice presidential running mate, says he’s “fascinated” by the therapeutic potential of psychedelics, asking podcaster Joe Rogan for advice on a creating a possible “pathway” for providing access to substances such as MDMA and psilocybin for military veterans with serious mental health conditions.
Vance told Rogan that his overall philosophy on marijuana and psychedelics is “live and let live,” and he reaffirmed that he feels people should not be criminalized over cannabis. The podcast host also gave the senator a history lesson on marijuana prohibition that Vance said he had “no idea” about.
While the candidate has previously discussed his position that states should have the right to set their own cannabis policies, this is the first time he’s publicly weighed in on laws around psychedelics, though he made clear he’s “not committing to some public policy” and needs to “be careful with this stuff, especially six days from an election.”
After Rogan described research on the medical value of psychedelics and the lack of access to such substances under the current federal drug scheduling statute—as well as the racially discriminatory history of marijuana prohibition—Vance said he “had never heard about” those particular points.
“I’m a veteran too. I spent four years in the Marine Corps—went to Iraq, went to Haiti once,” he said. “What is the pathway, I guess? Or what do you think should happen for veterans accessing psychedelics?”
Rogan told the senator “there are so many anecdotal stories about veterans experiencing relief that I think it should be available to them, especially veterans.”
Vance followed up, inquiring about whether psychedelics access would be incumbent on approval by the Food and Drug Administration (FDA).
“If it had a medical use, presumably, you would get it off of Schedule I [of the Controlled Substances Act (CSA)]. So why aren’t we—I’m just fascinated by this. This is the first time I’ve heard about this,” the senator said.
Hellbound and Down 
You must be logged in to post a comment.